Concept of Polycystic Ovarian Syndrome: Perspectives of Ayurveda and Modern Science

Patel M G¹, Prajapati D P²*

¹Department of Pharmacognosy, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Waghodia, Vadodara.
²Department of Pharmacognosy, Parul Institute of Pharmacy and Research, Faculty of Pharmacy, Parul University, Waghodia, Vadodara.

Received: 12th Sep, 17; Revised 10th Oct, 17, Accepted: 18th Oct, 17; Available Online: 25th Oct, 17

ABSTRACT
Polycystic ovarian syndrome is a hormonal disorder affecting 12-18% women of reproductive age. Women with PCOS have irregular menstrual cycle, excess of androgens, insulin resistance, serum lipids alteration, anovulation, acne, hirsutism and infertility. According to Ayurveda this type of clinical features are found in Pushpadhni jataharni (disease similar to Polycystic ovarian syndrome mostly having hyperandrogenism and anovulatory cycle) and Nashtartva (no proper growth of follicles and chronic anovulation). It involves the imbalance of dosha, dhatu and upadhatu. Evidence based medical management of PCOS is done by controlling irregular menses, treatment of hirsutism and acne, management of infertility and insulin resistance. The chemical based drugs induce ovulatory cycle in women, instead of allowing it to restore to its original healthy rhythm. The successful treatment of infertility is usually possible in the majority of patients with PCOS by using natural, non-invasive and non-chemical remedies. The present review provides information about some herbal plants, extracts of plants, active constituents from plants and some formulations clinically tested in animal models inducing PCOS and humans suffering from PCOS.

Keywords: Polycystic ovarian syndrome, anovulation, hyperinsulinemia, Ayurveda, dosha.

INTRODUCTION
Polycystic ovarian syndrome (PCOS) may clinically be manifested in young women of reproductive age as oligo-ovulation, biochemical or clinical hyperandrogenism, hirsutism, male pattern baldness, acne, acanthosis nigricans and polycystic ovaries. But PCOS has a long prodrome with detectable abnormalities that present as the metabolic syndrome like hyperinsulinemia, obesity, dyslipidemia related to decrease high density lipoprotein cholesterol and hypertriglyceridemia, hypertension, atherosclerosis, increased risk of development of type II diabetes and cardiovascular disease throughout the life of affected women¹.

PCOS is a heterogeneous disorder that affects at least 7% of adult women. According to the National Institute of Health Office of Disease Prevention, PCOS affects approximately 5 million women of child bearing age. Research suggests that 5-10% of females at 18 to 44 years of age are affected by PCOS making it the most common endocrine abnormality among women of reproductive age².

As no specific sole cause of PCOS has been determined, the most accepted evidence is a multifactorial model where interactions between environmental cues and factors intrinsic to individual act in consonance towards a common result, which is development of hyperandrogenemia, a biochemical hallmark of this pathology. This alteration is the main culprit behind most clinical manifestations of PCOS. There are no single criteria sufficient for clinical diagnosis because of multiple aetiologies and presentations. Though globally it has an alarming incidence, its diagnosis is difficult as it manifests as a spectrum of symptoms rather than a specific one³.

Pathophysiology
Modern perspective of PCOS
PCOS has a heterogeneous etiology involving a variety of combination of reproductive, metabolic and genetic determinants. No single etiology has so far been found to have particular predictive power in explaining the occurrence of PCOS. Furthermore no single etiological gene or inheritance pattern has been found for occurrence of PCOS. Clearly improvements in our understanding of the developmental process causing PCOS are necessary to clarify the relative importance of the multifactorial components in PCOS development and to focus clinical initiative in prevention, diagnosis and treatment.

PCOS is imbalance of female sex hormones. The ovaries are the part of female reproductive system along with uterus, fallopian tubes and vagina. The ovaries contain the lifetime supply of eggs. These eggs are immature and stored in tiny fluid filled follicles. Pituitary gland located at the base of brain produces hormones which direct the function of ovaries. Each
month the pituitary gland secretes Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) in blood stream. After these hormones reach the ovaries several hundred immature eggs start maturing expanding the size of follicles which simultaneously secretes estrogen, the main female sex hormone. Once the level of estrogen reaches to certain level, the pituitary gland senses the surge of luteinizing hormone to the ovaries causing the most mature follicle to release the egg called ovulation. The free egg travels the fallopian tube where it awaits fertilization, eventually the remaining follicles and eggs dissolve. If the egg is not fertilized the lining of uterus sheds during the menstruation.

In PCOS the pituitary gland releases abnormally high amount of Luteinizing hormone in blood stream disrupting the normal menstruation cycle. As a result the follicle does not mature and ovulation does not occur which can lead to anovulation. The immature follicle which does not dissolve remains as fluid filled sacs or cysts. These cysts lead to a hormonal imbalance because of an increased amount of testosterone. This can result in acne, an increase in facial and body hair and irregular periods.

In addition there is high level of insulin hormone produced by pancreas. Insulin combines with luteinizing hormone and lead to excess production of male hormone testosterone in ovaries. Abnormally high amount of testosterone in the ovaries prevent ovulation which can lead to infertility. Along with it, PCOS raises the risk of Type II diabetes because of excess of insulin or insulin resistance, heart disease, high blood pressure, cholesterol abnormality and endometrial cancer4.

Irregular periods
When you have PCOS, the hormone activity becomes irregular as ovulation is not occurring in an expected way. The body gives mixed signals and the menstrual cycle is disrupted. Periods can vary widely from woman to woman. It can change from irregular, infrequent periods (oligomenorrhea) or heavy to absent periods (amenorrhea)3.

Insulin resistance
Insulin resistance accompanied by compensating hyperinsulinemia (elevated fasting blood insulin level) is important biochemical feature of PCOS. Hyperinsulinemia increases ovarian androgen production (particularly testosterone and androstenedione) and decreases the sex hormone binding globulin (SHBG) concentration6.

Research at the University of Oxford and The Imperial College London revealed that a gene implicated in the development of obesity is also linked to susceptibility to PCOS. A study revealed that elevated levels of androgen than normal subjects were found in mothers and sisters of patient suffering from PCOS. It is also manifested that PCOS is genetically transferred ovarian syndrome and it is heterogeneous disorder which involves the interaction of the other genes with the environment7.

Histomorphology of ovaries
Polycystic ovaries are six fold larger than normal ovarian size. There is large number of immature follicles (subcortical cysts) which causes the change in the shape of ovary. The ovary becomes whitish in color and there is multiple cystic follicles covered by a dense fibrous capsule. There is luteinization of the theca cells (hyperthecosis) and thickening of tunica albugenia (connective tissue covering the ovaries)3.

Changes in hormonal level
The ovarian and adrenal glands of women with PCOS are usually the sites of production of elevated androgens. It is also proposed that women with PCOS have a hyper production of CYP17 enzyme, which is found to be responsible for forming androgens in the ovaries and adrenals5. Ovaries makes several androgens of which testosterone is the most prominent others include androstenedione and dehydroepiandrosterone (DHEAS). The most typical feature of polycystic ovary is the stroma and theca cells make excessive of testosterone10.

Signs and Symptoms
The major signs and symptoms related to PCOS includes menstrual disturbances ranging from amenorrhea to oligomenorrhagia to episodic menometrorraghia with anemia, hyperandrogenism, increased muscle mass, androgenic alopecia, deepening of voice, clitoromegaly, hirsutism, acne, insulin resistance, acanthosis nigricans, dyslipidemia, infertility and miscarriage11.

Diagnosis
Women may have cysts in the ovaries for a number of reasons and so it is the characteristics constellation of symptoms, rather than the presence of cysts themselves that is important in establishing the diagnosis of PCOS. The Rotterdam criteria of assessment: presence of two out of the following three criteria:

- Oliomenorrhea and/or anovulation
- Hyperandrogenism (clinical and/or biochemical)
- Polycystic ovaries with exclusion of other etiologies.

The other methods of diagnosis are gynecological ultrasonography, laparoscopic examination which reveals a thickened, smooth, pearl white outer surface of the ovary, serum (blood) elevated levels of androgens (male hormones), including androstenedione, testosterone and dehydroepiandrosterone sulphate, the ratio of Luteinising hormone and Follicle stimulating hormone being greater than 1:1 as on the day 3 of menstr
tual cycle, reduced levels of sex hormone binding globulin (SHBG), fasting biochemical and lipid profile, prolactin to rule out hyperprolactinemia, TSH to rule out hyperthyroidism3.

Ayurvedic perspective of PCOS
Ayurveda describes PCOS to have an equal involvement of the Doshas, Dhatu and Upadhatu. It does not correlate the condition to a single disease or syndrome but the symptoms bears a resemblance to the terminologies defined as Anartava- Amenorrhea, Yoniyapad-anatomical and physiological disorder of the reproductive system like Arjaska- oligomenorrhoea due to vitiation of vata dosha, Lohitakshaya- oligomenorrhoea due to vitiation of vata-pitta dosha, Vandhya-Infertility, Pushpaghni- Revati- Idiosyncratic anovulatory menstruation, Abeejata- anovulation, Rajodshiti and Ashartava Dushhti- Menstrual flow disorder due to vitiation of Dosha, Shandhi Yoniyapad- Vitation of vata
due to genetic factors causes menstrual irregularities which may or may not be associated with anovulation. Vishama ahara and vihara (improper diet and activities) which causes reduced digestion and metabolism leading to immaturity of digestive extract and formation of immature rasa which vitiates menstrual blood and leads to increase in meda dhatu and kapha which causes

| Name of Drug                  | Part/ extract used | Dosage          | Animal Model          | Parameters used                                                                 |
|-------------------------------|-------------------|-----------------|-----------------------|---------------------------------------------------------------------------------|
| Thuya occidentalis            | Oil               | 500 mg/kg       | Letrozole induced PCOS model | Serum gonadotropins, steroids, blood lipid, leptin and glucose. Histopathology of ovaries |
| Tephrosia purpurea            | Seed powder       | 0.2 gm/kg       | Letrozole induced PCOS model | Ovary weight, Hormonal assay, Testosterone, Luteinizing Hormone, Follicle stimulating hormone, Estrogen |
| Camellia sinensis             | Green tea         | 50, 100, 200 mg/kg | Estradiol valerate induced PCOS model | Examination of Estrous cycle |
| Labisia pumila                | Entire herb       | 50, 100, 200 mg/kg | Dihydrotestosterone induced PCOS model | Hormonal assay, histological study of ovary |
| Nardostachys jatamansi        | -                 | -               | Estradiol valerate induced PCOS in rat | Antiandrogenic activity, estrous cyclicity, steroidal hormone levels |
| Tribulus terrestris           | -                 | -               | Estradiol valerate induced PCOS in rat | Antiandrogenic activity, estrous cyclicity, steroidal hormone levels |
| Symplocos racemosa            | Aqueous extract of stem bark | 250-1000 mg/kg | Letrozole induced PCOS rat model | Ovarian and uterine weight, hormonal assay, histology of ovaries |
| Aloe barbadensis              | Gel from leaves   | 10 mg/day       | Letrozole induced PCOS rat model | Insulin sensitivity by OGTT, steroidogenic enzyme assay. Histological examination of ovaries |
| Commiphora makul             | Gum-guggulu       | 40 mg/100 gm body weight | Letrozole induced PCOS rat model | Estrous cycle is monitored by daily examination of vaginal smear, body weight, histomorphometry of ovary, western blot analysis of IL-6 in ovarian tissue. Determination of C-protein, testosterone, superoxide dismutase, catalase, LPO, etc. |
| Commiphora wightii            | Ethanic extract   | 100 mg in sesame oil | Dehydroepiandrosterone (DHEA) induced PCOS in rats | Measurement of body weight, ovary weight, liver weight. Serum analysis T3, T4, TSH, FSH, LH, Testosterone, estradiol, progesterone, histology of ovaries |
| Saraca asoca                 | Bark extract      | 500 mg/kg /kg body weight | Estrogenicity in adult female overiectomised mice | Induction of estrous cycle, detrimination of size and weight of uterus |
| Mentha piperita               | Herbal tea        | 40 gm/l         | Letrozole induced PCOS rat model | Hormonal analysis, histomorphology of ovary and uterus, immunohistochemical investigations in ovary. Study of vaginal smears. |
| Pergularia daemia             | Fresh juice       | -               | Testosterone propionate induced PCOS model | |
| Corylus avellana              | Seed oil          | 2 ml/day        | Letrozole induced PCOS rat model | Determination of serum gonadotropins, serum lipids, leptin, glucose levels, histology of ovary. |
| Mimosa pudica Linn.           | Aqueous extract   | 250,500 and 1000 mg/kg | Letrozole induced PCOS rat model | Determination of testosterone, estrogen, progesterone,cholesterol levels, weight of ovary and uterus was determined, histology of ovary was done. |
obstruction of body channels and vata prakopa causing obesity and amenorrhoea. Vata and Kapha doshas as well as vishama aahar and vihara leads to reduced digestive fire and causes production of Ama (undigested food). This ama production causes improper enzymatic reactions leading to incomplete metabolism and hormonal imbalance. This hormonal imbalance causes hyperinsulinemia and hyperandrogenism ultimately leading to anovulation and amenorrhoea/oligomenorrhoea and ovarian abnormalities like polycystic ovaries.

Ayurveda does not speak in the terms of “hormones”. It has its own unique language and terms. Hormones are considered as fire elements in the tissue. The action of hormones expresses the nature of pitta, the energy responsible for transformation. All stages of the female reproductive process are a result of the interplay of hormones. The fact behind the alteration of each stage is due to pitta replicated in the effect of the hormones on the various stages of the ovarian and menstrual cycles. If pitta predominates it manifests as hair loss, acne, painful menses, clots and heart problems.

Kapha’s heavy cool qualities nourish the development of the tissues that form and support the reproductive system as well as vata and paras leading to reduced digestive fire and causes Ama, obesity and amenorrhoea. Ama is reliable for affecting the movement of the follicle during the ovarian cycle, the breakdown of the ovary wall for releasing the matured ovum, the movement of the fimbriae - directs the ovum into the fallopian tubes and the movements of the ovum near the uterus. The predominance of vata is manifested as painful menses, scanty or less menstrual blood and severe menstrual irregularity.

Management of PCOS

Allopathic management of PCOS

The medical management of PCOS can be divided in to four components: three of them are acute issues which include control of irregular menses, treatment of hirsutism and management of infertility. One that is more chronic is the management of insulin resistance syndrome.

To regulate menstrual cycle, combination of birth control pills containing both estrogens and progestin are used. The birth control pills decrease androgen production and give body a break from the effects of continuous estrogen, lowering the risk of endometrial cancer and correcting abnormal bleeding. To treat the hirsutism Co-cyprinol and Efornithine can be used. Eflorznithine is a topical cream that has been

Table 2: Formulations screened for PCOS.

| Name of formulation | Dosage | Animal Model/ Clinical Trail | Parameters used |
|---------------------|--------|------------------------------|-----------------|
| Stanya Gana | 10 gm bd in empty stomach with luke warm water | 30 year old women with PCOD | Changes in menstrual cycle, changes in ovarian volume with USG, ovulation etc. |
| Gynocare | 1 capsule per day | Women with PCOS | Chronically irregular menstruation (CIM), Ovarian size, Obesity, Acne, Hairloss and Hirsutism. Hb %, TLC, DLC, ESR, USG. |
| Ugyanetone forte capsules | 2-3 tablespoon twice daily | Open labeled non comparative study for female patients aged between 12-55 and fulfilling ESHRE/ ASRM Rotterdam criteria for PCOD, 2003 | BMI, duration of infertility, acne, hirsutism, obesity, oligomenorrhea |
| Evecare syrup | 750 mg bd | Double blind placebo controlled study in women aged above 18 years suffering from infertility due to PCOS presenting with symptoms such as hirsutism, acne and obesity | Pelvic pain, irregular menstruation cycle, USG of uterus and ovaries. |
| Gana | Tablet twice a day | Open observational trail in women with PCOS | Regularity or irregularity of menstrual cycle, hirsutism, ovulation, no. of cysts, size of ovary, serum insulin level, BMI |
| Rasayana-herbomineral formulation | 25.31 mg rasayana/200 gm body weight | Letrozole induced PCOS model | Determination of ovarian cycle, ovarian histomorphology, hormonal assay for plasma testosterone, progesterone and estrogen. |
| Mehani | 50 mg/100 gm body weight | Testosterone propionate induced PCOS model | Determination of androgens. |
Pharmacological management includes clomiphene citrate. Aromatase inhibitors are offered to the multifactorial women with PCOS who have anovulatory and infertile. Clomiphene citrate can also be incorporated in the therapy for PCOS. The successful treatment of infertility is usually possible in the majority of patients with PCOS by using natural, non-invasive and non-chemical remedies. The herbal therapies are found to restore the normal rhythm of the menstrual cycle by balancing the hormones and also they are found to restore the imbalance of doshas occurring due to anovulation. Moreover there are herbs having phytoestrogens are available which can also be helpful in the treatment of disease. The plants maintaining the level of insulin and lipid lowering herbs can also be incorporated in the therapy for PCOS. The following tables provide the information about the drugs approved by the US Food and Drug Administration for removal of unwanted facial hair in females. Eflornithine inhibits the enzyme ornithine decarboxylase in the skin, which inhibits cell division and synthetic functions, thus reducing the rate of hair growth. It should be used twice daily, at least 8 hours apart, on the affected areas of the face and chin.

The management of infertility can be done using non-pharmacological and pharmacological approach. The first line non-pharmacological management of PCOS can be done by life style management which targets weight loss and prevention of weight gain and includes both reduced dietary energy intake and exercise. While the first line pharmacological treatment is clomiphene citrate which improves fertility. It is partially selective estrogen receptor modulator. Its antiestrogenic activity at the hypothalamus induces a change in gonadotropin releasing hormone (GnRH) pulse frequency leading to increased release of follicle stimulating hormone (FSH) from the pituitary gland.

The second line pharmacological management includes Metformin combined with clomiphene citrate to improve fertility outcome rather than persisting clomiphene citrate alone in women with PCOS who are resistant to clomiphene citrate. Metformin if BMI < 30 Kg/m^2 can be used alone to improve ovulation rate and pregnancy rate in women with PCOS who are anovulatory and are infertile with no other infertility factors. Gonadotropins can be used as second line pharmacological therapy in women with PCOS who have clomiphene citrate resistance or failure, and are anovulatory and infertile. Aromatase inhibitors- Letrozole under caution can be offered as a pharmacological treatment for ovulation induction indicated for infertile anovulatory woman with PCOS. Laproscopic ovarian surgery and Bariatric surgery are also the options available.

PCOS has a complex ateiopathogenesis involving mostly a combination of reproductive, metabolic and genetic elements. No single prognostic element has been able to strongly explain the pathophysiology and occurrence of PCOS. Furthermore, no single etiological gene or inheritance pattern has been found for occurrence of PCOS. Obvious enhancement in our understanding of the various progressions causing PCOS are required to simplify the relative importance of the multifactorial components in PCOS development and to focus clinical initiative in prevention, diagnosis and treatment. Chemical based medications prescribed by allopathic medicines can be harmful to our body and have side effects including vaginal bleeding, blurred vision, nausea, ovarian hyper stimulation (ovarian enlargement), vomiting, flushing, breast tenderness, increased likelihood to multiple births, strokes, seizures, shortness of breath, etc.

These drugs chemically induce a women ovulatory cycle, instead of allowing it to be restored to its original healthy rhythm. The successful treatment of infertility is usually possible in the majority of patients with PCOS by using natural, non-invasive and non-chemical remedies. The herbal therapies are found to restore the normal rhythm of the menstrual cycle by balancing the hormones and also they are found to restore the imbalance of doshas occurring due to anovulation. Moreover there are herbs having phytoestrogens are available which can also be helpful in the treatment of disease. The plants maintaining the level of insulin and lipid lowering herbs can also be incorporated in the therapy for PCOS. The following tables provide the information about the drugs which were screened in animals as well as those who were clinically tested in the human volunteers. It also

---

**Table 3: Active constituents screened for PCOS.**

| Name of Active constituent | Dosage | Animal Model/ Clinical trail | Parameters used |
|----------------------------|--------|-------------------------------|----------------|
| a Thujone42                | -      | Letrozole induced PCOS model  | Serum gonadotropins, steroids, blood lipid, leptin and glucose. Histopathology of ovaries. |
| Berberine43,44,45          | 1.5 gm/day | Women with PCOS undergoing IVF treatment | Clinical, metabolic and endocrine effects of berberine. |
|                           | 500 mg three times a day | Multicenter randomized double blind trail | Antipometric measurements, serum concentration of TT, SHBG, insulin, glucose, TC, TG, HDTC, LDLC. |
| Curcumin46                | 100-200 mg/kg | Letrozole induced PCOS in female wistar rats | Hormonal assay, measurement of fasting blood glucose, glycocolated hemoglobin level, assessment of lipid profil, antioxidant assay for superoxide dismutase, catalase, reduced glutathione, ovarian histomorphology. |

---

*Patel et al. / Concept of Polycystic...*
| Name of Drug                | Part/ extract used | Dosage                | Clinical trail                  | Parameters used                                                                 |
|-----------------------------|-------------------|-----------------------|---------------------------------|---------------------------------------------------------------------------------|
| Asparagus racemosus (Shatavari) | Powder of root     | 5 gm twice a day      | 25-40 aged subfertility women   | Ultrasonography for changes in ovary, LH/FSH ratio                              |
| Anethum graveolens (Shatapushpa) | Seed powder        | 5 gm thrice a day     | 15-35 years women with oligomenorhoea | Hemoglobin %, weight of patient, amount of blood flow, subjective parameters like interval of menstruation, duration and pain throughout menstruation period |
| Shatapushpa taila           | Powder             | 5 gm twice a day      | 25-40 aged subfertility women   | Ultrasonography for changes in ovary, LH/FSH ratio                              |
| Tinospora cordifolia (Guduchi) | Powder             | 5 gm twice a day      | 25-40 aged subfertility women   | Ultrasonography for changes in ovary, LH/FSH ratio                              |
| Mentha spicata (Spearmint)  | Herbal tea         | Cup of tea twice a day| Female hirsute patients with PCOS | Levels of androgens                                                             |
| Glycyrrhiza glabra (Liquorice) | Powder             | 3.5 gm/day            | Clinical study in 32 women with PCOS | Blood pressure, BMI, Serum electrolytes, Plasma renin, Plasma aldosterone and cortisol, serum testosterone, urinary tetrahydrocortisol/cortisone ratio. Effect on Leutenising hormone (LH), Follicle stimulating hormone (FSH), change in ovary volume, effect on cyst, menstrual cycle and pregnancy, effect on hemoglobin level and total leucocyte count, plasma glucose, serum triglyceride, serum HDL cholesterol levels etc. Clinical assessment including menstrual cycle frequency, height, weight, BMI and hirsutism. Concentration of prolactin, LH, FSH, TSH, free testosterone, DHEA-S (dehydroepiandrosterone sulfate, 17α OHP/Hydroxy progesterone) , fasting glucose and insulin, SGPT, SGOT, etc. |
| Trigonella foenum graceum (Fenugreek) | Seed extract enriched with 40% furostanolic saponins (Furocyst) | 2 capsules per day | Multicentric, open labeled, single arm, non randomized study in female (18-45 years) suffering from PCOS. | Blood samples were assayed for glucose, insulin, FSH, LH, prolactin, TSH, testosterone, estradiol, and SHBG by chemoilluminescence. |
| Cinnamomum cassia           | Bark extract       | 1 gm per day          | 14 women with PCOS aged 20-35 years whose chief complaints were menstrual disturbances and infertility and/or clinical signs of hyperandrogenism | Blood tests included follicle-stimulating hormone (FSH), luteinizing hormone (LH) and progesterone. Transvaginal ultrasound was performed to document follicular size and growth as well as endometrial thickness. If a follicle achieved a size of 18 mm or greater, human chorionic gonadotropin (HCG) was given and then intercourse was recommended. |
| Cimicifuga racemosa         | Extract            | 40 mg/ day            | Women with PCOS                 |                                                                                  |
provides information about some herbal formulations which give combined effect in the treatment of PCOS.

CONCLUSION
Polycystic ovary syndrome is a complex disorder with multiple etiologies for which multiple treatment approaches are required depending on the reason a patient seeks treatment. To treat PCOS one needs controlled and balanced diet and exercise for weight reduction along with medication and lifestyle management. Modern and traditional management together can have better results. Thus adopting a holistic treatment, good life style with
appropriate diet, yoga, pranayamas and stress free living can prove to be effective in the management of PCOS.

REFERENCE

1. Allahabadia GN and Merchant R. Polycystic ovary syndrome in the Indian Subcontinent. Seminars in Reproductive medicine 2008; 6(1): 22-34.
2. Anadu U, Ndeo A, Eaton A, Robinson MG. Polycystic Ovary syndrome. Pharmacy and Therapeutics 2013; 38(2): 338-355.
3. Khandelwal R, Dipti, Nathani S. An Ayurvedic Approach to PCOS: A Leading Cause of Female Infertility. International Journal of Ayurveda & Medical Science 2016; 1(3); 77-82.
4. Polycystic ovarian syndrome, Nucleus medical media, 2011.
5. Sereno M. Polycystic Ovarian Syndrome. Merck Sereno Australia Pvt. Ltd., Australia, 2011, 8-9.
6. Mishra D and Sinha M. Ayurvedic Management of Polycystic Ovary syndrome (Infertility Queen). Journal of Research and Education in Indian Medicine 2008; 14(1): 33-40.
7. Frank S, McCarthy MI, Hardy K. Development of Polycystic Ovary syndrome: Involvement of Genetic and Environmental Factors. International Journal of Andrology 2006; 29(1): 278-285.
8. Krishnamurthy MS and Hebbbar. Polycystic ovarian syndrome: Ayurvedic treatment, Remedies, Diet. Easy Ayurveda 2009, Health and Lifestyle blog.
9. Haywood A and Bone K. Phyotherapy for Polycystic Ovary Syndrome (PCOS). A Phytotherapeutics Perspective 2004; 46(1): 1-6.
10. Nagarathna PKM, Rajan PR, Koneri R. A detailed study on Polycystic Ovary syndrome and its treatment with natural products. International Journal of Toxicological and Pharmacological Research 2014; 5(4): 109-120.
11. Wonggokusuma G. The pathophysiology and treatment of Polycystic Ovary syndrome: A systematic review. CDK-213 2014; 41(2): 100-103.
12. Rotterdam ESHRE/ASRM sponsored Polycystic Ovary syndrome consensus workshop. Consensus on diagnostic criteria and long term health risks related to Polycystic Ovary syndrome: fertility and sterility 2004, 81:19-25.
13. Kadam R, Shinde K, Kadam R, Kulkarni M. Contemporary and Traditional Perspective of Polycystic Ovary syndrome (PCOS): A critical review. IOSR Journal of Dental and Medical Sciences 2004; 13(9): 89-98.
14. Raju NK, Diagnostic and Therapeutic approach to Polycystic Ovary syndrome to Ayurveda. Ayurvedaline.
15. Ade JS, Madgundi AK, Deore SS. Polycystic Ovary syndrome: An Ayurvedic perspective W.S.R. kriya Sharir- Review article. International Journal of Applied Ayurvedic Research 2014; 1(8):1-5.
16. Sheehan MT. Polycystic Ovary syndrome: Diagnosis and Management. Clinical Medicine and Research 2004; 2(1): 13-27.
17. Sirmans SM and Pote KA. Epidemiology, diagnosis and management of Polycystic Ovary syndrome. Clinical epidemiology 2013; 6(1): 1-13.
18. Evidence based guidelines for the assessment and management of Polycystic Ovary syndrome. Centre for research excellence in Polycystic Ovary syndrome 2016-17.
19. www.grocare.com/blog/tag/ Polycystic Ovary syndrome-treatment medications.
20. Akkola EK, Ilhana M, Demirelb MA, Kelesc H, Tunem I, Suntara I. Thuja occidentalis L. and its active compound α-thujone : promising effect in the treatment of Polycystic Ovary syndrome without inducing osteoporosis. Journal of Ethnopharmacology 2015; 168(1): 25-30.
21. Thakor AP, Patel AJ. Normalizing of estrous cycle in Polycystic Ovary syndrome induced rats with Tephrosia purpurea Linn. Journal of applied and natural science 2014; 6(1): 197-201.
22. Ghafurniyani H. The effect of Green tea extract on reproductive improvement in estradiol valtere induced Polycystic Ovary syndrome in rats. Iranian journal of Pharmaceutical Research 2015; 14(4): 1215-1233.
23. Maneras L, Fazliana M, Wan Nazaimoon WM, Lonn M, Gu HF, Ostenson CG, Stener-Victorin E. Beneficial metabolic effects of the Malaysian herb Labisia pumila var. alata in a rat model of PCOS. Journal of Ethnopharmacology 2010; 127(2): 346-351.
24. Palarhil S, Movilavalappil, Toine B, Krishnan S. Antiandrogenic activity of Nardostachys jatamansi DC and Tribulus terrestris Linn and their beneficial effects on Polycystic Ovary syndrome- induced rat model. Metabolic syndrome and related disorders 2015; 6(1): 248-254.
25. Jadhav M, Menon S, Shailajan S. Antiandrogenic effect of Symplocos racemosa Roxb. Against letrozole induced Polycystic Ovary syndrome using rat model. Journal of coastal life medicine 2013; 1(4): 309-314.
26. Maharajan R, Nagar PS, Napoothiri L. Effect of Aloe barbadensis Mill. Formulation on letrozole induced Polycystic Ovary syndrome rat model. Journal of Ayurveded and Integrative medicines 2010; 1(4): 273-279.
27. Pandey V, Shukla R, Krishna A. Effect of combined treatment of Modern and herbal supplement in the management of letrozole induced Polycystic Ovary syndrome. Journal of Endocrinology and Chemistry 2013; 4(1): 1-6.
28. Kavitha A, Narendra BA, Sathish KM, Veena KS. Evaluation of effects of Commiphora wightii in Dehydroepiandrosterone (Dhea) induced Polycystic Ovary Syndrome (Pcos) In Rats. PharmaTutor 2016; 4(1): 47-55
29. Deka A. Determination of Estrogenicity of (Saraca asoca Linn.,) Asoca plant in adult female ovarietomised mice. International Journal of Recent Scientific Research 2015; 6(12): 7661-7664.
30. Amoura MA, Lotfy ZH, Neveen ER, Khloud AE. Potential effects of Mentha piperita (peppermint) on Letrozole- induced polycystic ovarian syndrome in female albino rat. International Journal of Advanced Research 2015; 3(10): 211-226.

31. Segaran B, Rajan P, Horne IA. Detection of Polycystic Ovary Syndrome and Its Treatment with Pergularia daemia in Rat Models. IOSR Journal Of Pharmacy 2015; 5(5): 42-49.

32. Murdes AD, Mert I, Ipek S, Hikmet K, Esra KA. Activity of Coriylus avellana seed oil in letrozole-induced polycystic ovary syndrome model in rats. Revista Brasileira de Farmacognosia 2016; 5(1): 83–88.

33. Jadhav M, Menon S, Shailajain S. In Vivo Evaluation Of Mimosa Pudica Linn. in The Management Of Polycystic Ovary Using Rat Model. International Journal of Applied Biology and Pharmaceutical Technology 2013; 4(1): 285-292.

34. Kale PD and Dei LP. Management of Artav Dushiti (W.S.R to Polycystic Ovary syndrome) by virechana and Sanyta soadhana gana: A single case study. European journal of Pharmaceutical and medical research 2016; 3(3): 500-503.

35. Raman S and Palep HS. Alternative therapies in Polycystic Ovary syndrome. Bombay hospital Journal 2010; 52(3): 345-351.

36. Patil M, Deshpande S, Bal A, Thosar S, Yende M. Multicentric study to evaluate safety and efficacy of Ugyanetone forte capsules in treatment of Polycystic Ovary syndrome. International Journal of Innovative and Applied Research 2015; 3(1): 32-36.

37. Sharma HK and Sharma RK. Evaluation of efficacy and safety of Evecare syrup in infertility due to PCOS. International Journal of Clinical Practice 2010; 21(2): 38.

38. Mangal U and Mangal A. Ayurvedic modality on Polycystic Ovary syndrome- A case report. International Ayurvedic Medical Journal 2016; 4(11): 19-22.

39. Pandya M, Golwala D, Khanderia K. Evaluation of clinical efficacy and safety of Ovaryl tablet an herbal formulation in Polycystic Ovary syndrome. International Journal of Obstetrics and Gynecology research 2015; 2(2): 73-91.

40. Kumari VH, Sarasheeti RS, Hadimir KS, Patil KA. Effect of herbomineral formulation (Shilajatu rasayana) in letrozole induced Polycystic Ovary syndrome. BLDE university journal of health sciences 2016; 2(2): 11.

41. Pushpa NL and Kalavathy S. Effect Of Mehoni On Hormonal Profile In Wistar Rats Induced With Polycystic Ovary Syndrome. Biology 2013; 1(1): 21-24.

42. Akkola EK, Ilhana M, Demirel MA, Keles H, Tumend I, Sunara I. Thuja occidentalis L. and its active compound α-thujone : promising effect in the treatment of Polycystic Ovary syndrome without inducing oestoporosis. Journal of Ethnopharmacology 2015; 168(1): 25-30.

43. Yuan A, Sun Z, Zhang Y, Liu B, Guan Y, Lu M. The use of berberine for women with Polycystic Ovary syndrome undergoing IVF treatment. Clinical endocrinology 2014; 80(5): 425-431.

44. Li Y, Kuang H, Shen W, Ma H, Zhang Y, Victorin ES, Hung E, Ng Y, Liu J,Kuang H, Hou L, Wu X. Letrozole , berberine or their combinations for anovulatory infertility in women with PCOS: study design of a double blind randomized controlled trial. BMJ journals 2013; 3(11): 1-6.

45. Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, Ma Y, Zhang Y, Zhang H. A clinical study on the short term effect of berberine in comparison to metformin on the metabolic characteristics of women with Polycystic Ovary syndrome. European Journal of Endocrinology 2012; 166(1): 99-105.

46. Reddy FS, Begum N, Mutha S, Bakshi V. Beneficial effect of Curcumin in letrozole induced Polycystic Ovary syndrome. Asian Pacific Journal of Reproduction 2016; 5(2): 116-122.

47. Dayani SA, Sariwardene LP, Karunathiloka PA, Kodituwakku ND, Karuanarathne YA. Clinical efficacy of Ayurveda treatment regime on infertility due to Polycystic Ovary syndrome. AYU 2010; 31(1): 24-27.

48. Ghosh A and Panda PK. Anetham sova kurz. Powder in the management of Artava kshaya (Oligomenorrhoea). AYU 2010; 31(4): 447-450.

49. Dayani SA, Sariwardene LP, Karunathiloka PA, Kodituwakku ND, Karuanarathne YA. Clinical efficacy of Ayurveda treatment regime on infertility with Polycystic Ovary syndrome. AYU 2010; 31(1): 24-27.

50. Patel KD, Dei L, Donga SB, Anand N. Effects of Shatapushpa Taila Matra Basti and Pathadi Kwatha on Polycystic ovarian disease. AYU 2012; 33(2): 243-246.

51. Akgogan M. Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. Phytotherapy Research 2007; 21(5): 444-447.

52. Grant P. Spearmint herbal tea has significant antiandrogen effects in Polycystic Ovary syndrome; A randomized controlled trial. Phytotherapy Research 2009; 24(2): 186-188.

53. Armanaini D. Treatment of Polycystic Ovary syndrome with spironolactone and Liquorice. European Journal of Obstetrics Gynecology and Reproductive Biology 2007; 131(1): 61-67.

54. Swaroop A, Jaipuria AS, Gupta S, Bagchi M, Kumar P, Preuss HG, Bagchi D. Efficacy of a Novel Fenugreek seed extract (Trigonella foenum graceum, FurocystTM) in Polycystic Ovary syndrome. International Journal of medical sciences 2015; 12(10): 825-831.

55. Bashtian MH, Emami SA, Mousavifar A, Poor AH. Evaluation of Fenugreek (Trigonella foenum graceum L.) effects seed extract on insulin resistance in women with PCOS. International Journal of Pharmaceutical Research 2013; 12(2): 475-481.

56. Wang JG, Anderson R, Nakhuda GS, Guaraccia MM, Sauerand MV, Lobo RA. The effect of
cinnamon extract on insulin resistance in polycystic ovary syndrome: A pilot study. Fertility and Sterility 2007; 88(1): 240-243.

57. Kamel HH. Role of phyto-oestrogens in ovulation induction in women with polycystic ovarian syndrome. European Journal of Obstetrics and Gynecological Reproduction Biology 2013; 168(1): 60-63.